相关实验视频

Updated: Jan 15, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

韦萨托利莫德在EAE中的神经保护作用:调节免疫平衡和微质极化

Xueyu Chen¹, Jian Zhang¹, Shuhua Mu²

¹School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen 518055, China.

International journal of molecular sciences

|October 16, 2025

概括

韦萨托利莫德 (VES) 通过减少神经炎症和增强神经功能,有效地治疗实验性自身免疫脑膜炎 (EAE),一种多发性硬化症 (MS) 模型. 这种托尔类受体7 (TLR7) 激动剂对MS治疗具有前景.

科学领域:

神经免疫学神经免疫学
药理学药理学是指药理学的学科.
自免疫性疾病自免疫性疾病

背景情况:

多发性硬化症 (MS) 是一种慢性中枢神经系统自身免疫性疾病,具有神经炎症和脱髓化.
韦萨托利莫德 (VES) 的治疗潜力,一个Toll-like受体7 (TLR7) 激动剂,在神经炎症条件,如MS在很大程度上未被探索.

研究的目的:

为了评估VES在实验性自身免疫脑膜炎 (EAE) 鼠标模型中MS的疗效.
阐明VES在神经炎症中的治疗作用背后的机制.

主要方法:

在小鼠中使用髓寡细胞糖蛋白 (MOG35-55) 诱导EAE.
通过临床评分,体重监测,组织病理学,流细胞测量,蛋白质组学和西欧斑块来评估治疗效果.
使用体外微质激活模型研究细胞自主机制.

主要成果:

VES显著改善了EAE临床评分,减少了体重减轻,并增强了神经功能.
VES抑制了促炎的Th1/Th17细胞和扩大调节性T细胞 (Tregs).
VES保留了血脑屏障的完整性,减少了脱髓化,调节了微质激活,并激活了Nrf2/HO-1抗氧化途径.

结论:

在EAE中,VES表现出多模式治疗效果,包括免疫调节,BBB保护和抗氧化剂防御激活.
这些发现支持VES作为多发性硬化症治疗的有希望的治疗候选者.

关键词:

Nrf2 路径的路径维萨托利莫德 (Vesatolimod) 是一种可以使用的方法.实验性的自身免疫性脑膜炎.微质分极化微质分极化多发性硬化症多发性硬化症神经炎症是一种神经炎症.

更多相关视频

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...